VRTX Q3 2018 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$785M+35.7% YoY

Gross Profit

$673M85.8% margin

Operating Income

$206M26.2% margin

Net Income

$129M16.4% margin

EPS (Diluted)

$0.50

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

$381M

Free Cash Flow

$360M

Stock-Based Comp.

$86M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$1.7B

Stockholders' Equity

$2.9B

Cash & Equivalents

$2.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$785M	$578M	+35.7%
Gross Profit	$673M	$505M	+33.2%
Operating Income	$206M	-$326M	+163.1%
Net Income	$129M	-$103M	+225.1%

Revenue Segments

ORKAMBI

$282M36%

SYMDEKO/SYMKEVI

$255M33%

KALYDECO

$246M31%

Geographic Segments

UNITED STATES

$620M68%

Non-US

$164M18%

Europe

$133M14%